0.19 USD
↗ 0.00 (1.21%)AT CLOSE (03:59 PM EDT)
TScan Therapeutics, Inc. Common Stock
TCRXNASDAQ • USD
0.19
↗ 0.00 (0.00%)
POST MARKET (AS OF 05:47 PM EDT)
Post Market
AS OF 05:47 PM EDT
0.19
↗ 0.00 (0.00%)
Market: OPEN
Shares of TScan Therapeutics, Inc. Common Stock (TCRX) are trading at $0.19. The stock presents a bearish profile across the board: technical indicators signal "Sell" and our fundamental models agree with a "Sell" rating. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest TCRX is trading at a discount to its peers, earning an "Attractively Valued" rating.
Technical & fundamental data as of Oct 27, 2026.
Open?$0.19
High?$0.20
Low?$0.18
Prev. Close?$0.19
Volume?540.8K
Avg. Volume?674.5K
VWAP?$0.19
Rel. Volume?0.80x
Bid / Ask
Bid?$0.16 × 100
Ask?$0.22 × 100
Spread?$0.06
Midpoint?$0.19
Valuation & Ratios
Market Cap?12.9M
Shares Out?63.5M
Float?55.3M
Float %?87.2%
P/E Ratio?N/A
P/B Ratio?0.19
EPS?-$1.74
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Themes
Employees
142
Market Cap
12.9M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2021-07-16
Address
830 WINTER STREET
WALTHAM, MA 02451
Phone: 857-399-9500
WALTHAM, MA 02451
Phone: 857-399-9500
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?6
Z-Score?0
Momentum?50
Short Sent.?54
Piotroski F-Score?1/9Weak
Altman Z-Score?-6.29Distress
Confidence?56%Low
Short InterestModerate
Short % of Float?4.11%Low
Short Interest?2.3M
Days to Cover?3.4
Free Float55.3M
Avg Daily Volume669.4K
Settlement Date2026-10-15
Financial Health
Current Ratio?3.37Strong
Quick Ratio?3.37Strong
Cash Ratio?3.23Strong
Debt/Equity?0.47Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?0.19CHEAP▾
Peers100
S&P97
P/S?1.81CHEAP▾
Peers100
S&P71
P/FCF?N/A▾
EV/EBITDA?0.5CHEAP▾
Peers100
S&P97
EV/Sales?-7.66CHEAP▾
S&P97
Returns & Efficiency
ROE?-170.6%WEAK▾
S&P3
ROA?-68.7%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-118439000
Enterprise Value?$-54498943
Fundamentals ratios updated end of day